SDP Completes Tolero Buy To Build Oncology Ahead Of Key Expiry

Sumitomo Dainippon Pharma has completed the acquisition of US specialty company Tolero for up to $780m in a move that boosts the mid-sized Japanese firm's presence in oncology ahead of a looming major patent expiry for its top-selling product.

US Japan

Sumitomo Dainippon Pharma Co. Ltd. (SDP) has paid $200m upfront for Lehi, Utah-based Tolero Pharmaceuticals Inc., and agreed further milestone payments of up to $430m related to the progress of Tolero's pipeline, plus up to $150m in post-launch commercial milestones based on net sales of commercialized Tolero-sourced products.

The deal, first announced in late December, immediately gives DSP a portfolio of six development-stage molecules in oncology, including hematologic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip